KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Expenses (2016 - 2025)

CRISPR Therapeutics AG's Operating Expenses history spans 11 years, with the latest figure at $155.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 55.2% year-over-year to $155.6 million; the TTM value through Dec 2025 reached $668.1 million, up 32.59%, while the annual FY2025 figure was $668.1 million, 32.59% up from the prior year.
  • Operating Expenses for Q4 2025 was $155.6 million at CRISPR Therapeutics AG, up from $132.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $230.2 million in Q2 2025 and bottomed at $100.3 million in Q4 2024.
  • The 5-year median for Operating Expenses is $145.2 million (2024), against an average of $149.1 million.
  • The largest annual shift saw Operating Expenses skyrocketed 71.04% in 2021 before it fell 27.44% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $158.6 million in 2021, then dropped by 17.06% to $131.5 million in 2022, then rose by 0.06% to $131.6 million in 2023, then decreased by 23.81% to $100.3 million in 2024, then skyrocketed by 55.2% to $155.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Operating Expenses are $155.6 million (Q4 2025), $132.9 million (Q3 2025), and $230.2 million (Q2 2025).